盐酸右美托咪定(Dexmedetomidine Hydrochloride) - 药物靶点：ADRA2_在研适应症：躁郁症1型，躁郁症2型，精神分裂症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole、(+)-4-((S)-α,2,3-trimethylbenzyl)imidazole、dexmedetomidine

+ [21]

靶点

ADRA2

作用机制

ADRA2激动剂(肾上腺素能受体α-2家族激动剂)

治疗领域

其他疾病神经系统疾病

在研适应症

躁郁症1型躁郁症2型精神分裂症+ [10]

非在研适应症

原研机构

在研机构

+ [12]

非在研机构

Pfizer Inc.

四川百利药业有限责任公司

Maruishi Pharmaceutical Co., Ltd.

最高研发阶段批准上市

首次获批日期

美国 (1999-12-17),

镇静

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (美国)、快速通道 (美国)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C13H17ClN2

InChIKeyVPNGEIHDPSLNMU-MERQFXBCSA-N

CAS号145108-58-3

关联

4,291

项与盐酸右美托咪定相关的临床试验

CTRI/2024/10/075414

/ Not yet recruiting临床4期

Efficacy of external oblique intercostal block (EOIB) with or without dexmedetomidine on postoperative anaglesia in laparoscopic upper abdominal surgeries – a double blinded randomised control trial - Nil

开始日期2027-09-01

申办/合作机构

All India Institute of Medical Sciences

NCT06685965

/ Not yet recruiting临床2期

Double-Blind, Randomized, Placebo-Controlled, Crossover, Laboratory Based Study With Rollover Extension to Evaluate Safety of Short-term Use of RE03 in Home Setting in Post-Traumatic Stress Disorder (PTSD) Patients With Sleep Disturbances

Post-traumatic stress disorder (PTSD) affects many people who have experienced traumatic events. A common issue with PTSD is severe sleep disturbances, such as nightmares. Current treatments often do not provide sufficient relief, especially for sleep problems. This study aims to determine whether dexmedetomidine - a medication already used in intensive care - can improve sleep quality in PTSD patients and be safely administered both in the sleep lab and in the patient's natural environment.

开始日期2025-04-01

申办/合作机构

Reconnect Labs

[+1]

NCT05619627

/ Not yet recruiting临床1期IIT

Utility of Oral Dexmedetomidine as the Sole Sedative Agent in Pediatric Population Undergoing MRI

The objective of this preliminary study is to assess the utility of oral dexmedetomidine as the sole sedative agent in pediatric population undergoing MRI

开始日期2025-03-01

申办/合作机构

The Children's Mercy Hospital

100 项与盐酸右美托咪定相关的临床结果

登录后查看更多信息

100 项与盐酸右美托咪定相关的转化医学

登录后查看更多信息

100 项与盐酸右美托咪定相关的专利（医药）

登录后查看更多信息

11,174

项与盐酸右美托咪定相关的文献（医药）

2025-04-01·DEN open

Feasibility of non‐anesthesiologist‐administered sedation with dexmedetomidine and midazolam during endoscopic submucosal dissection of upper gastrointestinal tumors

Article

作者: Ishido, Kenji ; Tanabe, Satoshi ; Matsuda, Hiromi ; Kitahara, Gen ; Furue, Yasuaki ; Kusano, Chika ; Watanabe, Akinori ; Wada, Takuya ; Okamoto, Hirotsugu

Abstract:

Objectives:

The efficacy and safety of a sedation regimen combining dexmedetomidine and midazolam during endoscopic submucosal dissection for upper gastrointestinal tumors remains unclear. In this study, we aimed to evaluate the efficacy and safety of this sedation regimen, where non‐anesthesiologists performed sedation.

Methods:

Sixty‐eight patients who underwent endoscopic submucosal dissection for upper gastrointestinal tumors, sedated by non‐anesthesiologists, were retrospectively evaluated. The sedation was performed by non‐anesthesiologists as part of on‐the‐job training (OJT) under anesthesiologists' supervision. Each non‐anesthesiologist received OJT at least thrice. Proficiency levels were assessed during the third OJT session. The target sedation depth was a Richmond Agitation‐Sedation Scale of −2 to −4, with 2 L/min of oxygen delivered via a nasal cannula at sedation initiation. The treatment completion rates, which measured efficacy and safety, were assessed by the frequencies of respiratory depression, hypotension, and bradycardia.

Results:

The study included 14, 52, and two patients with superficial esophageal cancer, early gastric cancer, and gastric adenoma, respectively. The median treatment time was 68 and 84 min for superficial esophageal cancer, early gastric cancer, and adenoma, respectively. Endoscopic submucosal dissection was completed in all patients. No severe sedation‐related adverse events were reported; however, peripheral arterial oxygen saturation <90%, hypotension, and bradycardia occurred in 1 (1.5%), 30 (44.1%), and 30 patients (44.1%), respectively. All 22 non‐anesthesiologists who underwent the proficiency evaluation passed the test.

Conclusions:

A sedation regimen combining dexmedetomidine and midazolam can be feasibly administered by non‐anesthesiologists. Further studies are needed to verify the effectiveness of OJT.

2025-02-01·BIOMATERIALS

Multiple sclerosis treatments a review of current biomedical engineering approaches

Review

作者: Au, Kin Man ; Issa, Wadih ; Wang, Andrew Z ; Stuve, Olaf ; Ruan, Lifu ; Mohseni, Sayyed Ourmazd ; Wang, Andrew Z.

Multiple Sclerosis (MS) is an autoimmune condition targeting the central nervous system (CNS) characterized by focal demyelination with inflammation, causing neurodegeneration and gliosis. This is accompanied by a refractory period in relapsing MS or chronic progression in primary progressive MS. Current MS treatments target disease relapses and aim to reduce further demyelination and disability. These include the treatment of acute exacerbations through global immunomodulation upon corticosteroid administration, which are accompanied by adverse reactions. Disease modifying therapies (DMTs) which provide targeted immunosuppression of T and B cells, and sequestration of leukocytes out of CNS, have led to further improvements in demyelination prevention and disease burden reduction. Despite their efficacy, DMTs are ineffective in remyelination, pathology reversal and have minimal effects in progressive MS. The advent of modern biomedical engineering approaches in combination with a better understanding of MS pathology, has led to the development of novel, regenerative approaches to treatment. Such treatments utilize neural stem cells (NSCs) and can reduce disease relapses and reverse damage caused by the disease through localized tissue regeneration. While at initial stages, pre-clinical and clinical studies utilizing NSCs and immune modulation have shown promising outcomes in tissue regeneration, creating a potential new era in MS therapy.

2025-02-01·AMERICAN JOURNAL OF OPHTHALMOLOGY

Efficacy of Dexmedetomidine as an Adjuvant to Local Anesthetics in Peribulbar Block: A Meta-analysis With Trial-Sequential Analysis

Review

作者: Amaral, Sara ; da Silva, Rodrigo Araujo Monteiro ; Viana, Patrícia ; Silott, Pedro Furlan ; Pereira, Eduardo Maia Martins

PURPOSE:

To assess the role of dexmedetomidine as an adjuvant to local anesthetics (LA) in enhancing the duration and quality of peribulbar blocks for ophthalmic surgeries.

DESIGN:

Systematic review with meta-analysis and trial sequential analysis Methods: We systematically searched MEDLINE, Embase, and Cochrane for randomized controlled trials (RCTs) involving adult patients undergoing ophthalmic surgery under peribulbar block, comparing LA alone versus LA + dexmedetomidine. Risk ratios (RR) and mean differences (MD) with 95% confidence intervals (CI) were computed using a random effects model. Sensitivity and trial-sequential analyses (TSA) were performed to assess inconsistencies, weight type II and II errors, and estimate the required information size of the samples for all endpoints.

RESULTS:

Sixteen RCTs (1,220 patients) were included. Compared with LA alone, dexmedetomidine was associated with prolonged (1) motor block duration (MD 65.01 minutes, p<0.001) and (2) sensory block duration (MD 81.94 minutes, p<0.001); (3) reduced intraocular pressure (IOP) (MD -2.6 mmHg, p<0.001), and (4) decreased need for supplemental injections (RR 0.44, p=0.007). Additionally, dexmedetomidine showed (5) longer time to analgesic request (MD 97.15 minutes, p<0.001) and (6) increased surgeon satisfaction (RR 1.52, p=0.01). Sensitivity analyses and TSA were consistent across all endpoints, and the required information size was achieved for most endpoints, indicating that pooled analyses were reliable and sample sizes were sufficient.

CONCLUSIONS:

Compared with LA alone, dexmedetomidine significantly prolonged sensory and motor block duration and the time to the first analgesic request; decreased IOP and the need for supplemental injections, while increasing surgeon satisfaction.

384

项与盐酸右美托咪定相关的新闻（医药）

2025-01-07

·米内网

第十一批国采12个品种备战！超900亿市场海思科亮了，独家注射剂称王，石四药、华海蓄力

精彩内容日前，第十批国采中选结果正式公布，新一批次国采在路上。神经系统药物是纳入国采品种数TOP4的治疗大类，在系列政策加持下，该大类市场跌宕起伏，格局持续洗牌。目前197个神经系统化药已有企业过评/视同过评，人福领跑过评榜；54个品种（以通用名计）已纳入国采，12个品种备战第十一批国采，石四药、华海等均有多个品种在列。跌宕起伏！超900亿市场人福称王，海思科亮了米内网数据显示，近年来中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端神经系统化药（不含生物药，下同）市场起起落落，但总体维持在900亿元以上的销售规模。近年来中国公立医疗机构终端神经系统化药销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局从治疗亚类看，其它神经系统药物占主导地位，近年来占比均超过20%；麻醉剂、止痛药位居第二、第三，且占比均呈逐年上升趋势；此外，精神兴奋药、精神安定药近年来占比也均在10%以上。 2024H1中国公立医疗机构终端神经系统化药亚类分布情况来源：米内网中国公立医疗机构药品终端竞争格局从用药途径看，注射剂为神经系统化药用药主途径，但近年来占比持续下滑；以片剂、胶囊剂等为代表的内服用药紧接在后，且占比逐年提升，2024上半年超过40%。 2024H1中国公立医疗机构终端神经系统化药用药途径来源：米内网中国公立医疗机构药品终端竞争格局 TOP20集团中，人福医药、石药集团、扬子江药业、恒瑞医药、恩华药业依次位列前五，其中人福医药稳居首位，且市场份额较2023年有所提升；从销售额增幅看，海思科、灵北、晖致、NAPP同比增长均达两位数。 2024H1中国公立医疗机构终端神经系统化药TOP5集团来源：米内网中国公立医疗机构药品终端竞争格局 TOP20洗牌！“一哥”易主，4款国产新药上榜 2024上半年神经系统化药TOP20产品中，地佐辛注射液稳居多年的龙头宝座不保，石药集团独家新药丁苯酞氯化钠注射液成功上位，注射用盐酸瑞芬太尼稳居第三。20个产品中有7个2024上半年销售额达10亿元以上，其中TOP3产品均超20亿元。 2024H1中国公立医疗机构终端神经系统化药TOP20产品来源：米内网综合数据库从销售额增长情况看，8个品种逆势上涨，其中有4个涨幅达两位数，海思科的独家新药环泊酚注射液涨约16%，4+7及扩围集采品种草酸艾司西酞普兰片、4家企业在销的枸橼酸舒芬太尼注射液均涨约14%，恩华药业独家在销的依托咪酯乳状注射液(含依托咪酯注射液)涨约12%。 TOP20产品中，丁苯酞氯化钠注射液、依达拉奉右莰醇注射用浓溶液、丁苯酞软胶囊、环泊酚注射液均为国产新药。其中，环泊酚注射液最早于2020年底获批，2021年通过谈判纳入全国医保乙类目录，2023年在中国公立医疗机构终端的销售额超过9亿元，2024上半年首次跻身神经系统化药TOP20产品。丙泊酚乳状注射液、草酸艾司西酞普兰片、奥氮平片、盐酸右美托咪定注射液、富马酸喹硫平片已被纳入国采。受第九批集采执行影响，丙泊酚乳状注射液2024上半年销售额同比下滑超26%，但销售量同比增长约47%。近年来中国公立医疗机构终端丙泊酚乳状注射液销售量情况（单位：万支/瓶）来源：米内网中国公立医疗机构药品终端竞争格局余下的11个品种中，地佐辛注射液、依托咪酯乳状注射液(含依托咪酯注射液)、胞磷胆碱钠片、氢溴酸加兰他敏注射液、注射用盐酸丙帕他莫暂无企业过评或视同过评；吸入用七氟烷已满足国采入围门槛，符合申报资格企业数达7家及以上。 30亿吸入剂在列！12个品种备战第十一批国采米内网数据显示，截至2025年1月6日，197个神经系统化药已有企业过评或视同过评。40个品种竞争激烈，过评企业数达10家及以上，其中有2个达30个以上，分别为对乙酰氨基酚片（36）、盐酸利多卡因注射液（31）。从企业过评情况看，人福医药、复星医药、华海药业、恩华药业、上海医药、华润医药、石家庄四药、扬子江药业、齐鲁制药等药企（以集团计）已过评的神经系统药物品种数达20个及以上，其中人福医药以29个品种领跑。在国家开展的八批九轮化药集采中，神经系统化药分别有6个、2个、10个、8个、3个、8个、3个、8个、6个品种被纳入其中，合计54个品种（不含落标品种），其中精神兴奋药、精神安定药分别有17、14个。第十批国采已顺利落下帷幕，第十一批国采在路上。除去已纳入的品种，目前神经系统化药还有12个品种符合申报资格企业数达7家及以上，满足国采门槛，包括3个抗癫痫药、3个麻醉剂、3个精神兴奋药、1个精神安定药、1个抗帕金森氏病药以及1个其它神经系统药物。暂未纳入国采且符合7家及以上的神经系统化药注：销售额低于1亿元用*代表来源：米内网综合数据库 12个通用名药品2023年在中国公立医疗机构终端的销售额合计超过60亿元，其中吸入用七氟烷超30亿元，阿戈美拉汀口服常释剂型超9亿元，多巴丝肼口服常释剂型超8亿元，氟伏沙明口服常释剂型、奥卡西平口服常释剂型超5亿元。从过评企业看，山东京卫制药、石家庄四药以3个过评品种领跑，北京福元医药、杭州领业医药、湖南洞庭药业、深圳泛谷药业、宜昌人福药业、浙江华海药业、重庆圣华曦药业等企业均有2个过评品种在列。资料来源：米内网数据库注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至2025年1月6日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

带量采购

2025-01-02

·drugs

Adverse Outcomes Seen With MS Disease-Modifying Drugs in Pregnancy

THURSDAY, Jan. 2, 2025 -- Disease-modifying therapy (DMT) use for multiple sclerosis (MS) in pregnancy is associated with certain adverse outcomes, including small for gestational age, according to a study published in the January issue of The Lancet Regional Health: Europe . Nadine Bast, from Ruhr University Bochum in Germany, and colleagues conducted a prospective cohort study to examine pregnancy and neonatal outcomes in patients with MS. A total of 2,885 DMT-exposed and 837 DMT-unexposed pregnancies were compared. The researchers found that exposure to DMTs was not associated with spontaneous abortions, preterm birth, or major congenital anomalies. Severe infections were rare but occurred more often in those exposed to fumarates (2.8 percent versus 1.0 percent in unexposed). Associations were seen for second-trimester and third-trimester natalizumab exposure and anti-CD20 exposure with systemic antibiotic use (odds ratios, 2.47, 1.75, and 2.16, respectively). Significant reductions in birth weight were seen in the sphingosine-1-phosphate group and the third-trimester natalizumab subgroup (β = −132 and −74 g, respectively). The sphingosine-1-phospate and anti-CD20 groups often had small-for-gestational-age neonates (odds ratios, 1.65 and 1.54, respectively); in the entire cohort, the rate exceeded the general German population rate (18.8 versus 10 percent). "Our findings are critical to improve future pregnancy recommendations in women with MS seeking pregnancy by combining established and emerging evidence and increasing the number of reported pregnancies," the authors write. The study was funded by pharmaceutical companies; several authors disclosed ties to the pharmaceutical industry. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果

2024-12-25

·米内网

【瞩目】倍特药业1类新药来袭！抢攻千亿市场

精彩内容日前，CDE官网显示，成都倍特药业申报的1类新药BPR-30221616注射液获得临床试验默示许可，拟用于治疗转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）。今年以来，公司有7款新药（4款1类新药）获批临床。 BPR-30221616注射液是倍特药业开发的一款化药1类新药，其临床申请于2024年10月11日获得CDE承办受理，同年12月23日获得临床试验默示许可，拟用于治疗转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）。转甲状腺素蛋白淀粉样变性（ATTR）是一种罕见进行性疾病，多发性神经病（ATTR-PN）和心肌病（ATTR-CM）为该病两种表现。在全球已上市的针对ATTR的药物中，辉瑞的氯苯唑酸表现亮眼，2023年全球销售额超过33亿美元。近年来辉瑞的氯苯唑酸全球销售情况（单位：百万美元）来源：米内网跨国上市公司数据库米内网数据显示，国内针对ATTR的在研新药中，阿斯利康的Eplontersen注射液提交NDA在审，ALXN2220注射液处于III期临床；锐正基因的ART001注射液处于I/IIa期临床，尧唐(南京)生物的YOLT-201注射液步入I期临床，倍特药业的BPR-30221616注射液获批临床等。在国家医保目录中，ATTR-PN、ATTR-CM划分在神经系统类别中。米内网数据显示，近年来中国三大终端六大市场（统计范围详见本文末）神经系统化药（不含生物药）销售额均超过1000亿元。在该治疗领域，倍特药业的盐酸右美托咪定鼻喷雾剂已获批上市，水合氯醛糖浆报产在审，盐酸右氯胺酮鼻喷雾剂处于I期临床，BPR-30221616注射液获批临床等。倍特药业申报的部分神经系统化药新药来源：米内网中国申报进度（MED）数据库今年以来，倍特药业有7款新药获批临床，其中BPR-30221616注射液、HC022注射液、吸入用XQ-001、HC006注射液4款1类新药首次获批临床。今年以来倍特药业获批临床的新药来源：米内网中国申报进度（MED）数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至12月25日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 ●温馨提示● 因为微信公众号修改了推送规则，最近很多读者反映没有及时看到推文。把米内网设为“星标”，就能每天与我们不见不散啦，具体操作如下：【分享、点赞、在看】点一点不失联哦

申请上市临床申请临床3期上市批准

100 项与盐酸右美托咪定相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01205	盐酸右美托咪定	N05CM18	DB00633

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
躁郁症1型	美国	BioXcel Therapeutics, Inc.	2022-04-05
躁郁症2型	美国	BioXcel Therapeutics, Inc.	2022-04-05
精神分裂症	美国	BioXcel Therapeutics, Inc.	2022-04-05
镇静	美国	Hospira, Inc.	1999-12-17

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
痴呆	临床3期	美国	BioXcel Therapeutics, Inc.	2022-04-27
躁郁症	临床3期	美国	BioXcel Therapeutics, Inc.	2020-02-24
精神运动性激动	临床3期	美国	BioXcel Therapeutics, Inc.	2020-02-24
分裂情感性障碍	临床3期	美国	BioXcel Therapeutics, Inc.	2020-01-24
躁动	临床3期	澳大利亚	Hospira, Inc.	2011-02-01
谵妄	临床3期	澳大利亚	Hospira, Inc.	2011-02-01
苏醒期谵妄	临床3期	美国	Hospira, Inc.	2007-04-01
髋部骨折	临床3期	美国	Hospira, Inc.	2007-04-01
麻醉	临床3期	美国	Hospira, Inc.	2006-12-01
入睡和睡眠障碍	临床2期	瑞士	Reconnect Labs	2025-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04528173 (CTgov)	临床4期	睡眠异常 \| 麻醉 \| 扁桃体炎	35	Fentanyl+Morphine (Traditional Care Group (TCG))	簾構顧鏇糧鑰糧廠觸顧(選艱醖夢築繭構鹹積餘) = 廠憲餘網蓋壓膚憲積夢構繭鹹構簾範繭襯獵齋 (範鹹繭築襯醖憲鏇鏇願, 淵窪積醖積築鹹醖淵製 ~ 顧鹽鑰鏇鏇鏇壓選憲鏇) 更多	-	2024-12-20
				Dexmedetomidine+ketorolac (Opioid-Free Group (OFG))	簾構顧鏇糧鑰糧廠觸顧(選艱醖夢築繭構鹹積餘) = 淵選鬱鏇願製鏇衊醖鹽構繭鹹構簾範繭襯獵齋 (範鹹繭築襯醖憲鏇鏇願, 醖構糧艱膚鏇選窪繭蓋 ~ 繭顧觸構艱繭衊鹹鹽簾) 更多
NCT05283083 (DecatSepsis, Pubmed \| Chest)	临床3期	脓毒性休克	90	Dexmedetomidine infusion	範網衊壓遞衊積選選鏇(鹹蓋獵齋齋蓋製餘窪顧) = 鬱遞觸鑰鹽積築衊製夢鬱鹹艱衊遞選願製顧夢 (鏇簾襯醖簾願積範獵襯, -78 ~ -3.4)	不佳	2024-12-01
NCT04734418 (Pubmed \| J Intensive Care) 人工标引	N/A	-	179	Remifentanil	齋網積鑰齋憲夢鏇網餘(製鹽鹹廠膚選窪衊遞壓) = 膚獵築觸構艱鑰鬱糧鹽壓繭膚餘壓積憲築壓夢 (鹹襯齋壓鑰憲選鹽積餘 ) 更多	不佳	2024-09-18
				Dexmedetomidine	齋網積鑰齋憲夢鏇網餘(製鹽鹹廠膚選窪衊遞壓) = 築齋選膚選製壓醖觸網壓繭膚餘壓積憲築壓夢 (鹹襯齋壓鑰憲選鹽積餘 ) 更多
NCT03770130 (Pubmed \| Int J Surg) 人工标引	早期临床1期	移植相关的疾病	330	Dexmedetomidine	願鹹鬱憲網願網餘糧繭(範獵簾鏇糧獵顧鑰鏇選) = 築鏇觸築鹹築糧鏇壓觸壓鑰壓膚選衊範淵鹹廠 (觸齋淵積淵積繭艱鹹糧 )	不佳	2024-09-01
				Normal Saline	願鹹鬱憲網願網餘糧繭(範獵簾鏇糧獵顧鑰鏇選) = 齋蓋積餘齋窪鹹網鹽齋壓鑰壓膚選衊範淵鹹廠 (觸齋淵積淵積繭艱鹹糧 )
Pubmed \| Drug Des Devel Ther	N/A	认知功能障碍	80	Dexmedetomidine	鹽壓衊網廠夢衊鬱壓獵(觸製鬱廠廠衊壓襯簾鏇) = 鹹遞襯齋鹽蓋餘膚膚選築構範簾遞顧遞淵膚顧 (餘膚簾積廠選蓋蓋選窪 ) 更多	积极	2024-08-01
				Placebo	鹽壓衊網廠夢衊鬱壓獵(觸製鬱廠廠衊壓襯簾鏇) = 製醖蓋鑰膚餘餘襯壓齋築構範簾遞顧遞淵膚顧 (餘膚簾積廠選蓋蓋選窪 ) 更多
NCT03844841 (Pubmed)	临床4期	-	-	Dexmedetomidine	鏇網鹽衊鹽選願餘遞醖(淵築窪蓋選窪繭築醖鬱) = 網壓顧襯鬱鏇鬱鬱鏇鹹積糧壓網餘艱獵鏇夢餘 (餘積積膚觸餘憲網觸製 ) 更多	积极	2024-07-31
				Propofol	鏇網鹽衊鹽選願餘遞醖(淵築窪蓋選窪繭築醖鬱) = 壓糧糧選遞鹽鹹壓鬱膚積糧壓網餘艱獵鏇夢餘 (餘積積膚觸餘憲網觸製 ) 更多
NCT02053766 (CTgov)	N/A	线粒体病	19	Dexmedetomidine (Dexmedetomidine (Precedex®))	窪廠獵願鏇製願鬱憲淵(衊鹽餘構鹽窪襯壓艱衊) = 遞夢憲築願憲鑰築衊齋觸獵膚繭選衊繭糧構鑰 (鏇顧衊廠壓築顧艱鏇艱, 築淵膚夢製簾選膚構襯 ~ 繭蓋積觸憲淵網鏇衊衊) 更多	-	2024-07-17
				Propofol (Propofol)	窪廠獵願鏇製願鬱憲淵(衊鹽餘構鹽窪襯壓艱衊) = 憲齋艱製鹹築襯觸廠壓觸獵膚繭選衊繭糧構鑰 (鏇顧衊廠壓築顧艱鏇艱, 窪蓋遞鬱鹹繭選範顧窪 ~ 積窪簾網餘醖醖構廠艱) 更多
NCT01887184 (CTgov)	临床3期	胃肠道疾病	50	Placebo (Normal Saline)	選鑰觸齋願範鏇齋衊獵(遞鏇齋鏇鑰選獵艱鑰衊) = 選鬱鬱襯艱範襯醖襯範廠蓋鹽構襯醖製襯網範 (鹹願蓋襯願獵願觸夢艱, 網鏇鹽網蓋獵蓋範鏇構 ~ 繭鏇鹹鬱簾獵襯選顧製) 更多	-	2024-07-11
				Dexmedetomidine (Dexmedetomidine)	選鑰觸齋願範鏇齋衊獵(遞鏇齋鏇鑰選獵艱鑰衊) = 夢鏇齋蓋鑰積壓鹽築淵廠蓋鹽構襯醖製襯網範 (鹹願蓋襯願獵願觸夢艱, 積壓壓製觸鑰鹽憲鑰獵 ~ 憲壓觸餘鹽襯繭顧顧淵) 更多
Company_Website 人工标引	N/A	躁郁症 \| 精神分裂症	28	IGALMI	艱範鏇鹹糧遞構範鬱範(構窪醖鬱壓願憲範遞願) = Mean PEC score reduction was observed following all doses of IGALMI 膚製淵遞憲鏇襯簾選廠 (糧觸構蓋遞網蓋築窪鹽 ) 更多	积极	2024-06-25
NCT04042727 (C-RAD, CTgov)	临床2/3期	心房颤动	13	dexmedetomidine Hydrochloride (Dexmedetomidine Plus Standard of Care)	選範繭鹽築鑰鬱鬱醖醖(鏇窪顧網觸餘廠遞糧鹽) = 艱齋築糧選築糧夢鹹顧鏇憲鹹膚鹽選鏇觸積鹽 (範構餘鏇壓餘糧廠繭醖, 範齋憲窪繭願壓壓觸製 ~ 網簾蓋淵艱窪構選積獵) 更多	-	2024-06-04
				Normal saline (Placebo Plus Standard of Care)	選範繭鹽築鑰鬱鬱醖醖(鏇窪顧網觸餘廠遞糧鹽) = 夢壓糧遞衊壓艱窪淵餘鏇憲鹹膚鹽選鏇觸積鹽 (範構餘鏇壓餘糧廠繭醖, 遞積衊範膚繭醖齋鏇淵 ~ 壓鹽糧淵糧窪鑰製鹽願) 更多